Key Takeaways
- Federal Minister Syed Mustafa Kamal commended the 'Pakistan–China Pharmaceutical & Healthcare B2B Investment Conference 2026'.
- Expected agreements total around $850 million, including 16 deals and 80 MoUs.
- The minister highlighted the positive outcomes of the conference.
Federal Minister for National Health Services, Regulations and Coordination Syed Mustafa Kamal has expressed satisfaction over the successful conclusion of the 'Pakistan–China Pharmaceutical & Healthcare B2B Investment Conference 2026'.
In a statement issued on Saturday, the minister stated that the conference had yielded significant results, with an expected total value of around $850 million in agreements.
The minister further elaborated that these agreements encompassed 16 concrete deals and 80 Memorandum of Understanding (MoUs) between Pakistani and Chinese pharmaceutical companies.
Highlighting the importance of such collaborations, Minister Kamal noted, 'This conference has not only facilitated business opportunities but also strengthened our ties with China in the healthcare sector.'
The minister's statement came as a testament to the growing interest and investment potential within Pakistan’s pharmaceutical industry. The agreements are expected to bring substantial benefits, including technological advancements and enhanced market access.
According to official figures, the conference attracted participants from both countries, representing various segments of the pharmaceutical and healthcare industries. These include manufacturers, distributors, and research institutions.
The minister emphasized that the success of this investment conference is a significant step towards achieving the government's goal of promoting foreign direct investment in Pakistan’s healthcare sector.
In conclusion, Minister Kamal expressed optimism about future collaborations and reiterated his commitment to creating an enabling environment for such investments.
